Matthew Angel Purchases 231,482 Shares of Tempest Therapeutics (NASDAQ:TPST) Stock

Tempest Therapeutics, Inc. (NASDAQ:TPST) CEO Matthew Angel acquired 231,482 shares of the company’s stock in a transaction on Tuesday, March 24th. The shares were bought at an average price of $2.16 per share, with a total value of $500,001.12. Following the completion of the purchase, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at approximately $500,001.12. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tempest Therapeutics Stock Performance

TPST opened at $1.66 on Friday. The firm has a market cap of $8.18 million, a price-to-earnings ratio of -0.17 and a beta of -2.42. Tempest Therapeutics, Inc. has a twelve month low of $1.65 and a twelve month high of $12.23. The firm’s 50-day simple moving average is $2.39 and its 200-day simple moving average is $5.41.

Hedge Funds Weigh In On Tempest Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP acquired a new stake in Tempest Therapeutics during the 4th quarter worth $33,000. Sabby Management LLC acquired a new position in shares of Tempest Therapeutics during the 4th quarter worth about $513,000. Finally, Vanguard Group Inc. grew its position in shares of Tempest Therapeutics by 20.8% during the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock worth $1,671,000 after buying an additional 27,952 shares during the period. 22.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempest Therapeutics in a research report on Monday, December 29th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $12.50.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.